Press Releases Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
5.58 ^USD	-3.96%		-8.07%	+30.37%

May. 29	Transcript : Lantern Pharma Inc. - Special Call
May. 24	Lantern Pharma Files $150 Million Mixed Shelf	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lantern Pharma : Corporate Overview	Jun. 02	PU
Lantern Pharma : Corporate Overview	May. 13	PU
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights	May. 09	BU
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism	May. 06	BU
Lantern Pharma to Report First Quarter 2024 Operating and Financial Results on May 9th, 2024 at 4:30 p.m. ET	May. 03	AQ
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET	May. 02	BU
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	Apr. 25	AQ
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	Apr. 24	BU
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	Apr. 23	AQ
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	Apr. 22	BU
Lantern Pharma : Corporate Overview	Apr. 15	PU
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights	Mar. 18	BU
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284	Mar. 15	BU
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET	Mar. 11	BU
Lantern to Participate in H.C Wainwright and Co.'s 1st Annual Artificial Intelligence Based Drug Discovery and Development Virtual Conference	Mar. 06	AQ
Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points, Anticipates Reaching 100 Billion Data Points in 2024, paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines	Mar. 05	AQ
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference	Mar. 05	BU
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines	Mar. 04	BU
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers	Feb. 15	BU
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS and Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer	Jan. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Press Releases

Filters